HER2 tumor marker tests are used to determine whether breast cancer is HER2 positive or negative. A person is a candidate for ...

Preliminary results of an observational clinical trial underway at Roswell Park Comprehensive Cancer Center are shedding ...

The FDA approved tislelizumab-jsgr (Tevimbra) in combination with platinum and fluoropyrimidine-based chemotherapy as a first-line treatment for unresectable or metastatic HER2-negative (HER ...

A new research paper was published in Volume 16 of Oncotarget on June 17, 2025, titled "Molecular landscape of HER2-mutated ...

Vaccine may improve breast cancer treatment outcomes Dendritic cell vaccine shows potential to enhance chemotherapy effectiveness in HER2-postitive, ER-negative subtype Date: March 18, 2025 Source ...

Dr. Sara M. Tolaney discussed HER2-positive breast cancer, highlighting key trials, evolving treatment strategies, and the potential for improved outcomes.

DESTINY-Endometrial01 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Expressing Primary Advanced or Recurrent Endometrial Cancer ...

Send comments and news tips to [email protected]. Cite this: Sharon Worcester, MA. FDA Approves New ADC for HR+, HER2- Breast Cancer - Medscape - January 17, 2025.

One-third of HER2-positive (HER2+) tumors express the P95HER2 protein, which associates with an aggressive form of breast cancer with a poorer prognosis. Investigators of the Vall d'Hebron ...

The company is betting that the alternative cytotoxic payload in its ADC can overcome resistance in patients who relapse on Enhertu.

Results from SERENA-1 Parts K/L: A Phase 1 study of the next-generation oral selective estrogen receptor degrader (SERD) camizestrant (AZD9833) in combination with ribociclib in women with ER-positive ...